Allergic and Immunologic Conditions

The phase 3 IZAR-1 trial investigating sonelokimab in adults with active psoriatic arthritis (PsA) has met its primary endpoint, according to topline results announced by MoonLake Immunotherapeutics.

Prof. Raj Chovatiya shares his highlights from the Revolutionizing Atopic Dermatitis (RAD) 2026 meeting, reflecting on the key developments and discussions shaping the evolving management of atopic dermatitis.

Ruxolitinib cream has demonstrated efficacy and safety in adults with moderate atopic dermatitis. Dr Elaine Agius discusses a new TRuE AD4 analysis evaluating whether responses were consistent across different body sites, including sensitive areas such as the face and neck.

Targeting IL-36 signaling, imsidolimab significantly improved clear or almost clear skin responses at Week 4 compared with placebo in patients experiencing a generalized pustular psoriasis flare, with monthly maintenance treatment supporting sustained responses through 24 weeks.

Join us as leading experts discuss key data and perspectives from the late-breaking sessions at this year’s AAD meeting This March, experts from around the world gathered in Denver, Colorado, for the 2026 American Academy of Dermatology (AAD) Annual Meeting. ...

Founded by internationally recognised experts the IDS meeting brings together world leaders working across immune-activated skin conditions such as psoriasis, atopic dermatitis, alopecia areata, vitiligo and hidradenitis suppurativa. To capture key perspectives from the 2025 Summit, we spoke with editorial board member, Prof. Dedee Murrell, to bring you some of the key highlights from a selection of standout presentations delivered during the three-day event.

As 2025 draws to a close, it is clear that the past year has brought notable shifts across dermatology. To reflect on the developments that stood out most, members of our editorial board and recipients of our 2025 Future Leaders in Dermatology award share their perspectives, drawing on experience across subspecialties, regions and stages of career.

Early phase pooled results from 32 patients indicate that lonvoguran ziclumeran, a CRISPR-based gene-editing therapy, achieved durable, one-time disease control in hereditary angioedema (HAE). The phase 1/2 data demonstrated deep and sustained reductions in plasma kallikrein levels, with most patients remaining attack-free and prophylaxis-free for up to three years and a safety profile consistent with earlier findings.

Remibrutinib is a recently approved oral Bruton’s tyrosine kinase (BTK) inhibitor for CSU that has shown superior efficacy over placebo and a favourable safety profile in the pivotal phase 3 REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) trials. By inhibiting BTK, a central mediator of B-cell signalling and autoantibody production, remibrutinib may not only provide symptom relief and improves quality of life for patients with CSU, but could potentially modify the underlying disease mechanisms in autoantibody-positive patients and influence the long-term course of the condition. At the EADV Congress 2025, we had the pleasure of speaking with Prof. Martin Metz (Berlin, Germany), who presented new data on the immunomodulatory effects of remibrutinib. In our interview, Prof. Metz discusses the latest insights, explores how these findings could shape future clinical practice and reflects on the key questions that remain as research in this area continues to evolve.